<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">APM</journal-id><journal-title-group><journal-title>Advances in Precision Medicine</journal-title></journal-title-group><issn>2424-8592</issn><eissn>2424-9106</eissn><publisher><publisher-name>WHIOCE PUBLISHING PTE. LTD.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18063/apm.v6i1.233</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Fecal Microbiota Transplantation against Gut  Colonization Using a Multidrug-Resistant Organism</title><url>https://artdesignp.com/journal/APM/6/1/10.18063/apm.v6i1.233</url><author>LeeSeul Ki,ChoiJi Eun,ShinChae Min,KimMi-Na</author><pub-date pub-type="publication-year"><year>2021</year></pub-date><volume>6</volume><issue>1</issue><history><date date-type="pub"><published-time>2021-07-25</published-time></date></history><abstract>Background: Fecal microbiota transplantation against gut colonization using &amp;nbsp;a multidrug-resistant organism is a technique used to treat infections through &amp;nbsp;normalizing the gut microbiota via fecal microbiota transplantation in patients &amp;nbsp;with confirmed colonization by carbapenem-resistant Enterobacteriaceae (CRE) or vancomycin-resistant enterococci (VRE) based on a fecal culture &amp;nbsp;test within the past one week. In this study, we aimed to determine the safety &amp;nbsp;and effectiveness of this technique. Methods: The safety and effectiveness &amp;nbsp;were assessed via a systematic review. A literature search was conducted &amp;nbsp;using five Korean databases, such as KoreaMed, and international databases, &amp;nbsp;including Ovid-MEDLINE, Ovid-EMBASE, and Cochrane Library. Results: Main results are described here. From the studies retrieved using the &amp;nbsp;aforementioned search strategy, the remaining 581 studies were screened &amp;nbsp;using the inclusion and exclusion criteria, resulting in the selection of nine &amp;nbsp;studies for further consideration. In terms of safety, many studies reported &amp;nbsp;deaths and adverse reactions associated with different causes. Fewer studies &amp;nbsp;reported the rate of colonization; however, the effect of colony rate was &amp;nbsp;inconsistent when compared to no treatment group. Additionally, none of the &amp;nbsp;studies assessed the recurrence rate, a decrease in the prevalence of diseases &amp;nbsp;related to infection by multidrug-resistant bacteria, and the quality of life. &amp;nbsp;Conclusion: Fecal bacterial colonization for the decolonization of intestinal &amp;nbsp;multidrug-resistant bacteria was evaluated using a technique that requires &amp;nbsp;further research as there is insufficient literature evidence to validate its &amp;nbsp;safety and efficacy in treating infections through normalizing the intestinal &amp;nbsp;flora of patients with confirmed colonization by CRE or VRE.</abstract><keywords>Fecal microbiota transplantation,Gut colonization,Multidrug-resistant organism</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>1. Crouzet L, Rigottier-Gois L, Serror P. (2015). Potential Use of Probiotic and Commensal Bacteria as Non-Antibiotic Strategies against Vancomycin-Resistant Enterococci. FEMS Microbiol Lett, 362: fnv012.2. Ghani R, Mullish BH, McDonald JAK, et al. (2021). Disease Prevention not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized with Multidrug-Resistant Organisms. Clin Infect Dis, 72: 1444&amp;ndash;1447.3. Moher D, Liberati A, Tetzlaff J, et al. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, 6: e1000097.4. Huttner BD, de Lastours V, Wassenberg M, et al. (2019). A 5-Day Course of Oral Antibiotics Followed by Faecal Transplantation to Eradicate Carriage of Multidrug-Resistant Enterobacteriaceae: A Randomized Clinical Trial. Clin Microbiol Infect, 25: 830&amp;ndash;838.5. Sa&amp;iuml;dani N, Lagier JC, Cassir N, et al. (2019). Faecal Microbiota Transplantation Shortens the Colonisation Period and Allows Re-Entry of Patients Carrying Carbapenamase-Producing Bacteria into Medical Care Facilities. Int J Antimicrob Agents, 53: 355&amp;ndash;361.6. Battipaglia G, Malard F, Rubio MT, et al. (2019). Fecal Microbiota Transplantation Before or After Allogeneic Hematopoietic Transplantation in Patients with Hematologic Malignancies Carrying Multidrug-Resistance Bacteria. Haematologica, 104: 1682&amp;ndash;1688.7. Davido B, Batista R, Fessi H, et al. (2019). Fecal Microbiota Transplantation to Eradicate Vancomycin-Resistant Enterococci Colonization in Case of an Outbreak. Med Mal Infect, 49: 214&amp;ndash;218.8. Dinh A, Fessi H, Duran C, et al. (2018). Clearance of Carbapenem-Resistant Enterobacteriaceae vs Vancomycin-Resistant Enterococci Carriage After Faecal Microbiota Transplant: A Prospective Comparative Study. J Hosp Infect, 99: 481&amp;ndash;486.9. Bilinski J, Grzesiowski P, Sorensen N, et al. (2017). Fecal Microbiota Transplantation in Patients with Blood Disorders Inhibits Gut Colonization with Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clin Infect Dis, 65: 364&amp;ndash;370.10. Davido B, Batista R, Michelon H, et al. (2017). Is Faecal Microbiota Transplantation an Option to Eradicate Highly Drug-Resistant Enteric Bacteria Carriage? J Hosp Infect, 95: 433&amp;ndash;437.11. Jang MO, An JH, Jung SI, et al. (2015). Refractory Clostridium difficile Infection Cured with Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. Intest Res, 13: 80&amp;ndash;84.12. Stripling J, Kumar R, Baddley JW, et al. (2015). Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient with Clostridium difficile Colitis After Fecal Microbiota Transplant. Open Forum Infect Dis, 2: ofv078.13. Russell DL, Flood A, Zaroda TE, et al. (2008). Outcomes of Colonization with MRSA and VRE among Liver Transplant Candidates and Recipients. Am J Transplant, 8: 1737&amp;ndash;1743.14. United States Food and Drug Administration (U.S. FDA). Fecal Microbiota for Transplantation: Safety Alert &amp;ndash; Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. Viewed 7 April 2020, https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission.15. Agence Nationale de s&amp;eacute;curit&amp;eacute; du M&amp;eacute;dicament (ANSM). La Transplantation de Microbiote F&amp;eacute;cal et son Encadrement dans Les Essais Cliniques [Fecal Microbiota Transplantation and Its Supervision in Clinical Trials]. Viewed 1 September 2021, http://dev4-afssaps-marche2017.integra.fr/S-informer/Points-d-information-Points-d-information/La-transplantation-de-microbiote-fecal-et-son-encadrement-dans-les-essais-cliniques-Point-d-Information2.16. Keller JJ, Vehreschild MJ, Hvas CL, et al. Stool for Fecal Microbiota Transplantation Should be Classified as a Transplant Product and Not as a Drug. United European Gastroenterol J, 7: 1408&amp;ndash;1410.17. Scheeler A. (2019). Where Stool is a Drug: International Approaches to Regulating the Use of Fecal Microbiota for Transplantation. J Law Med Ethics, 47: 524&amp;ndash;540.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
